Last checked at 19 Aug 2015 15:09
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Reneuron Share News (RENE)
RENE Share
Price
RENE Share
News
RENE Share
Chat
RENE Share
Trades
RENE
Live RNS
RENE Share
Charts
RENE Level 2
Console
RENE Live
Share Price
RENE Broker
Ratings
RENE Directors
Deals
RENE Financial
Diary
RENE
Fundamentals
RENE Short
Positions
RENE
Media
Reneuron Information
- This share is currently suspended. It was suspended at a price of 3.275
Share Price Information for Reneuron (RENE)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
3.275
Bid:
0.00
Ask:
0.00
Change:
0.00 (0.00%)
Spread:
0.00 (0.00%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
3.275
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Angel Biotech signs new contract with ReNeuron
Mon, 05th Nov 2012 08:33
Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year.The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients. ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.On October 17th, Sharecast reported that news of progress in these trials would have a positive read-across for Angel, which has been supplying stem cells used in these trials. CM
More News
19 Aug 2015 05:21
18 Aug 2015 15:04
18 Aug 2015 05:10
17 Aug 2015 15:08
17 Aug 2015 05:19
14 Aug 2015 14:56
10 Jul 2015 09:05
ReNeuron raises £68.4m with Woodford support as annual losses widen
Stem cell therapy company Reneuron Group has raised £68.4m to focus on its core product and nanomedicine cancer programme through to the first half of 2019, while final results highlighted progress of its other projects. A placing of £68.4m at a price of 5p per share saw star UK fund manager Neil Wo
Read more